Although the revenue and EPS for UPS (UPS) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The headline numbers for Eagle Materials (EXP) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The headline numbers for American Tower (AMT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

While the top- and bottom-line numbers for Stanley Black & Decker (SWK) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Although the revenue and EPS for Ares Capital (ARCC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Although the revenue and EPS for Ecolab (ECL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

While the top- and bottom-line numbers for Hubbell (HUBB) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

The headline numbers for Spotify (SPOT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Although the revenue and EPS for Armstrong World Industries (AWI) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Spotify Technology S.A. (NYSE:SPOT ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Alex Norström - Chief Business Officer & Co-President Bryan Daniel Goldberg - Head of Investor Relations Christian Luiga - Chief Financial Officer Daniel G.

NNN REIT offers stable, conservative yields and a strong dividend growth track record, making it a solid choice for risk-averse, income-focused investors. The portfolio is highly diversified across resilient retail segments, with no major tenant concentration and a disciplined triple-net lease structure. While the risk profile is generally low, some exposure to cyclical and lower-credit tenants introduces minor risks compared to bond-like alternatives.

Boeing Co (NYSE:BA, ETR:BCO) reported a surge in revenue and a narrower loss for the second quarter, driven by increased commercial airplane deliveries and strong order intake. Revenue was up 35% year-over-year at $22.75 billion, above Wall Street estimates of $21.86 billion.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 29, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, …

BA narrows its Q2 loss and beats revenue estimates with 35% growth, driven by gains across all major business segments.

As Ford's Q2 report nears release, investors are eyeing whether its rich dividend can survive EV losses and tariff woes.

F5 (NASDAQ:FFIV) is set to report its earnings on Wednesday, July 30, 2025, after market close. For event-driven traders, understanding the stock's historical behavior around earnings releases can provide valuable insights, though actual results compared to consensus expectations will ultimately dictate market reaction.

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares jumped 25% at the open on Tuesday after the US Food and Drug Administration recommended the company lift a voluntary pause on shipments of its gene therapy ELEVIDYS for ambulatory Duchenne muscular dystrophy (DMD) patients. The regulator's move follows its determination that the death of an eight-year-old patient in Brazil, which had prompted a temporary halt, was unrelated to the therapy.

Cementos Pacasmayo's 2Q25 results confirm a positive regional demand trend, reversing years of decline and supporting revenue and margin growth. Improved operating leverage, higher EBITDA margins, reduced CAPEX, and debt reduction enhance distributable earnings and dividend potential. The stock offers the potential of a dividend yield that could reach 13% and trades at a low earnings multiple, with room for cyclical recovery and share price appreciation.

EWQ offers attractive value, robust dividend yield, and global diversification via French companies with significant international revenue streams. Key sectors—luxury, aerospace, energy, and healthcare—are poised for strong growth, offsetting France's modest economic outlook. The ETF's mix of defensive and growth industries, plus mid-cap exposure, creates a balanced risk/reward profile with superior historical performance.

Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.